CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
ACTHAR geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02030028
NCT02030028N/ACompleted

Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis

Dana Ascherman·interventional·Posted Jan 8, 2014·Updated Sep 6, 2023

In Brief

A clinical study evaluating ACTHAR gel for Rheumatoid Arthritis. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this research study is to evaluate if the study drug, ACTH Gel helps decrease the disease symptoms in people with Rheumatoid Arthritis (RA) who are already taking medications prescribed by their physician and are still experiencing disease symptoms. ACTH gel has been a Food and Drug Administration-approved treatment for Rheumatoid Arthritis since 1952, and in 2010 the FDA retained RA as a disease approved for ACTH gel use. Despite its FDA approval there is very limited data on its how well ACTH gel works in improving the symptoms of people with RA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMallinckrodt

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 8, 2014
Enrollment StartNov 1, 2014
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 12.5 years ago

Interventions

ACTHAR geldrug

Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.